A. Pippione

发表

Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease

Mauro Fasano, Tiziana Alberio, Leonardo Lopiano, 2012, Scientific Reports.

Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention

S. Oliaro-Bosso, D. Boschi, M. Lolli, 2017 .

Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.

D. Boschi, M. Lolli, A. Pippione, 2019, European journal of medicinal chemistry.

Parkinson's disease biomarkers in peripheral blood T lymphocytes: identification through a proteomic approach

A. Pippione, A. C. Pippione, 2013 .

A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats

J. Kaplanski, C. Cifani, D. Boschi, 2021, Brain sciences.

The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia

P. Circosta, D. Cilloni, G. Saglio, 2020, bioRxiv.

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety

P. Circosta, B. Rolando, S. Al-Karadaghi, 2022, Journal of medicinal chemistry.

Hydroxyazoles as acid isosteres and their drug design applications—Part 2: Bicyclic systems

D. Boschi, M. Lolli, A. Pippione, 2021, Advances in Heterocyclic Chemistry.

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action

A. Rosato, P. Carloni, E. Baloglu, 2017, Nature Communications.

Heterocyclic ring cleavage upon collision-induced dissociation of deprotonated 3-hydroxy-1,2,5-oxadiazoles (3-hydroxyfurazans).

Robert L. White, D. Boschi, M. Lolli, 2015, Journal of mass spectrometry : JMS.

N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK.

M. Kubbutat, J. Contreras, S. Al-Karadaghi, 2018, MedChemComm.

Hydroxyazoles as acid isosteres and their drug design applications—Part 1: Monocyclic systems

D. Boschi, M. Lolli, A. Pippione, 2021, Advances in Heterocyclic Chemistry.

Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres

Robert L. White, B. Rolando, K. Martina, 2018, Journal of Heterocyclic Chemistry.

Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches

K. Janda, K. Martina, F. Dosio, 2015 .

Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.

W. Y. Wahlgren, Elisabetta Marini, S. Oliaro-Bosso, 2018, European journal of medicinal chemistry.

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Biphenyl Moiety

P. Circosta, B. Rolando, S. Al-Karadaghi, 2021, Journal of medicinal chemistry.

Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.

A. Luganini, G. Gribaudo, D. Boschi, 2021, Antiviral research.

Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.

P. Circosta, B. Rolando, S. Al-Karadaghi, 2018, Journal of medicinal chemistry.

AKR1C3 is a biomarker and druggable target for oropharyngeal tumors

L. De Cecco, F. Perrone, P. Ostano, 2020, Cellular Oncology.

Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3.

W. Y. Wahlgren, Elisabetta Marini, B. Rolando, 2019, ACS medicinal chemistry letters.

Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.

C. Andrade, M. Piccinini, R. Friemann, 2017, European journal of medicinal chemistry.

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.

F. Dosio, D. Boschi, M. Giorgis, 2018, Recent patents on anti-cancer drug discovery.

Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies.

C. Andrade, B. Rolando, S. Al-Karadaghi, 2019, European journal of medicinal chemistry.

4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade.

M. Kubbutat, J. Contreras, S. Al-Karadaghi, 2017, MedChemComm.

New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold.

F. Spyrakis, B. Rolando, D. Boschi, 2022, European journal of medicinal chemistry.

Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.

Elisabetta Marini, C. Cena, D. Boschi, 2017, European journal of medicinal chemistry.